H-Tyr-D-Ala-Gly-Phe-Met-NH2结构式
|
常用名 | H-Tyr-D-Ala-Gly-Phe-Met-NH2 | 英文名 | H-Tyr-D-Ala-Gly-Phe-Met-NH2 |
|---|---|---|---|---|
| CAS号 | 61090-95-7 | 分子量 | 586.70300 | |
| 密度 | 1.286 g/cm3 | 沸点 | 1057.4ºC at 760 mmHg | |
| 分子式 | C28H38N6O6S | 熔点 | N/A | |
| MSDS | N/A | 闪点 | 593.3ºC |
H-Tyr-D-Ala-Gly-Phe-Met-NH2用途[D-Ala2]-Met-脑啡肽是一种阿片肽,是一种有效的阿片激动剂。[D-Ala2]-Met-脑啡肽通过中枢机制降低胆汁流量。[D-Ala2]-Met-脑啡肽具有镇痛作用[1][2]。 |
| 英文名 | 2-[[2-[[2-[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoylamino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide |
|---|---|
| 英文别名 | 更多 |
| 描述 | [D-Ala2]-Met-脑啡肽是一种阿片肽,是一种有效的阿片激动剂。[D-Ala2]-Met-脑啡肽通过中枢机制降低胆汁流量。[D-Ala2]-Met-脑啡肽具有镇痛作用[1][2]。 |
|---|---|
| 相关类别 | |
| 体内研究 | [D-Ala2]-Met-脑啡肽通过一种中枢机制降低Sprague-Dawley大鼠的胆汁流量[1]。动物模型:雄性Sprague-Dawley大鼠(250-320 g)[1]剂量:10、50、100、150和200 mg/kg给药:脑室内注射结果:胆汁流量减少12%至41%。胆汁中碳酸氢盐分泌减少。 |
| 密度 | 1.286 g/cm3 |
|---|---|
| 沸点 | 1057.4ºC at 760 mmHg |
| 分子式 | C28H38N6O6S |
| 分子量 | 586.70300 |
| 闪点 | 593.3ºC |
| 精确质量 | 586.25700 |
| PSA | 231.04000 |
| LogP | 2.29780 |
| InChIKey | ANZXICRKKYOVMY-UHFFFAOYSA-N |
| SMILES | CSCCC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)C(C)NC(=O)C(N)Cc1ccc(O)cc1)C(N)=O |
| 折射率 | 1.601 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
H-Tyr-D-Ala-Gly... 61090-95-7 |
| 文献:Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
| H-Tyr-D-Ala-Gly-Phe-Met-NH2上游产品 9 | |
|---|---|
| H-Tyr-D-Ala-Gly-Phe-Met-NH2下游产品 3 | |
| DAME |
| [D-Ala2]Met-enkephalinamide |
| D-Enkephalin |
| Met-enkephalinamide,ala(2) |
| [D-Ala2-Met5]enkephalinamide |
| Methionine-enkephalinamide,ala(2) |
| Enkephalinamide-met,ala(2) |
| Tyr-D-Ala-Gly-Phe-Met-NH2 |
| Dalamid |
| Dalamide |
| 2-Ala-met-enkephalinamide |
| Enkephalinamide-met,alanine(2) |
| [D-Ala2]-methionine enkephalinamide |
| H-Tyr-D-Ala-Gly-Phe-Met-NH2 |
| Enkephalin, Amide-[D-Ala2, Met5] |